Pharmaceutical Royalty Structures: A Global Technical Analysis
Executive Summary
In the pharmaceutical industry, royalties serve as a fundamental mechanism for sharing value from intellectual property and products.
Lilly’s TuneLab: accelerator, equaliser—or a gilded cage?
Eli Lilly’s latest act of corporate altruism arrived in September 2025 in the form of TuneLab, an artificial intelligence
The weekly term sheet (37)
Pharmaceutical & Biotech Transactions: September 8-14, 2025
Executive Summary
The week of September 8-14, 2025 witnessed 22 verified transactions in
Fractional Biotech Equity: From Experimental Concept to $1.3 Billion Alternative Funding Mechanism
Fractional equity funding for biotech companies - achieved through traditional securities divided into smaller units rather than cryptocurrency - has
Company of the week: Absci Corporation
Absci Corporation (NASDAQ: ABSI) stands at a pivotal crossroads in September 2025, having transitioned from a pure AI drug discovery
Fund of the Week: Neo Kuma Ventures – Europe's Psychedelic Medicine Specialist
Executive Summary
Neo Kuma Ventures, established in December 2020 as Europe's first venture fund dedicated to psychedelic healthcare,
Global Radiopharmaceutical Patent Wars
The radiopharmaceutical industry has erupted into an all-out patent war in 2024-2025, with Novartis at the center of a multi-billion
Radiopharmaceuticals: The Billion-Dollar Gold Rush Transforming Cancer Treatment
The Nuclear Medicine Revolution
In the corridors of global pharma, an unprecedented arms race is underway. The coveted weapons aren&
The biopharma royalty market crosses $14 billion in annual deal flow as competition intensifies
The biopharma royalty financing market has emerged as a critical pillar of life sciences funding, with annual transaction volume reaching
The weekly term sheet (36)
The first week of September 2025 saw a flurry of dealmaking in life sciences, with over $11.6 billion in
